Graham Capital Management, L.P. Adma Biologics, Inc. Transaction History

Graham Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.98 - $11.18 $106,025 - $198,221	-17,730 Reduced 56.69%	13,544 $151,000
Q1 2024 May 15, 2024	SELL	$4.4 - $6.74 $27,988 - $42,873	-6,361 Reduced 16.9%	31,274 $206,000
Q4 2023 Feb 14, 2024	BUY	$3.08 - $4.52 $29,044 - $42,623	9,430 Added 33.43%	37,635 $170,000
Q3 2023 Nov 22, 2023	SELL	$3.47 - $4.61 $37,222 - $49,451	-10,727 Reduced 27.55%	28,205 $100,000
Q2 2023 Aug 14, 2023	BUY	$3.12 - $4.22 $121,467 - $164,293	38,932 New	38,932 $143,000
Q2 2022 Aug 15, 2022	SELL	$1.43 - $2.2 $265,485 - $408,438	-185,654 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.28 - $1.83 $237,637 - $339,746	185,654 New	185,654 $339,000

319

185M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.91B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.